Nolpaza (Pantoprazole)

Pantoprazole, the active ingredient in Nolpaza, is a proton pump inhibitor presented as an injection solution for intravenous use. It reduces gastric acid secretion and is employed in the management of acid‑related disorders such as gastro‑oesophageal reflux disease, erosive esophagitis, Zollinger‑Ellison syndrome, and in the prevention of NSAID‑induced gastric ulcers in hospitalized patients.

GNH USA supplies Nolpaza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is distributed across European and global markets.

Nolpaza (pantoprazole) is used to treat acid‑related disorders by suppressing gastric acid production.

- Gastro‑oesophageal reflux disease (GERD): reduces acid exposure and promotes healing of esophageal mucosa. - Erosive esophagitis: facilitates ulcer resolution and symptom relief. - Zollinger‑Ellison syndrome: controls hypersecretion of gastric acid. - Prevention of NSAID‑induced gastric ulcers: lowers risk of ulcer formation in patients receiving NSAIDs.

Adverse reactions to Nolpaza may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Nausea: feeling of queasiness. - Diarrhea: loose stools. - Abdominal pain: discomfort in the stomach area. - Injection site reaction: redness or swelling at the infusion site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway compromise. - Clostridioides difficile infection: severe colitis associated with antibiotic use. - Hepatotoxicity: significant elevation of liver enzymes. - Thrombocytopenia: marked reduction in platelet count. - Stevens‑Johnson syndrome: rare severe skin reaction.

When using Nolpaza, clinicians should observe several precautionary measures to ensure patient safety.

- Assess renal function: adjust use in severe renal impairment. - Monitor electrolytes: watch for hypomagnesemia and related disturbances. - Evaluate for infection: increased risk of Clostridioides difficile colitis. - Use cautiously in hepatic impairment: monitor liver function tests. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nolpaza can affect the pharmacokinetics of several medicines; interactions should be reviewed before co‑administration.

Major Interactions (Avoid): - Rilpivirine: reduced absorption and antiviral efficacy. - Atazanavir: decreased plasma concentrations, risking treatment failure. - Methotrexate: increased toxicity due to reduced renal clearance. - Clopidogrel: diminished activation, potentially reducing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, monitor coagulation. - Digoxin: potential increase in serum levels, observe for toxicity. - Ketoconazole: decreased absorption, may require dose adjustment.